Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn’s disease-Reference-Cited by-同舟云学术

Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn’s disease

Published:2024-05-03 Issue:5 Volume:20 Page:297-305
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Faggiani Ilaria¹,D’Amico Ferdinando¹,Bernardi Francesca¹,Bencardino Sarah¹,Allocca Mariangela¹,Furfaro Federica¹,Parigi Tommaso Lorenzo¹,Zilli Alessandra¹,Fiorino Gionata¹²,Peyrin-Biroulet Laurent³⁴⁵⁶⁷,Danese Silvio¹

Affiliation:

1. Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy

2. IBD Unit, Department of Gastroenterology and Digestive Endoscopy, San Camillo-Forlanini Hospital, Rome, Italy

3. Department of Gastroenterology, University of Lorraine, CHRU-Nancy, Nancy, France

4. Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France

5. INSERM, NGERE, University of Lorraine, Nancy, France

6. INFINY Institute, Nancy University Hospital, Vandœuvre-lès-Nancy, France

7. Department of Gastroenterology, FHU-CURE, Nancy University Hospital, Vandœuvre-lès-Nancy, France

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2024.2349711

Reference60 articles.

1. Pathophysiology of Inflammatory Bowel Diseases

2. Crohn's disease

3. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease

4. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

5. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease